Insulin glargin

Insulin glargin
Klinički podaci
Prodajno ime	Lantus, Lantus OptiSet, Lantus SoloStar
Drugs.com	glargine.html Monografija
Način primene	Subkutano
Farmakokinetički podaci
Poluvreme eliminacije	30 h
Identifikatori
CAS broj	160337-95-1
ATC kod	A10AE04 (WHO)
DrugBank	DB00047
Hemijski podaci
Formula	C267H404N72O78S6
Molarna masa	6.062,96 g·mol−1
Fizički podaci
Tačka topljenja	81 °C (178 °F)

Insulin glargin je rekombinantni analog ljudskog insulina proizveden pomoću specializovane laboratorijske vrste bakterija Escherichia coli (K12). On je analog ljudskog insulina u kome je asparagine u poziciji A21 zamenjen glicinom i dodata su dva arginina na C-terminusu (u pozicijama B31 i 32) B-lanca. Rezultujući protein je rastvoran na pH 4 i formira mikroprecipitate na fiziološkom pH 7.4. Male količine insulin glargina se sporo oslovađaju iz mikroprecipitata što daje leku dugo vreme dejstva (do 24 sata) i odsustvo izraženog pika koncentracije.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Reference

^ Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Chatterjee, S.; Tringham, J. R.; Davies, M. J. (јул 2006). „Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus”. Expert Opin Pharmacother. 7 (10): 1357—71. PMID 16805721. doi:10.1517/14656566.7.10.1357.
^ Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;Dunn, C. J.; Plosker, G. L.; Keating, G. M.; McKeage, K.; Scott, L. J. (2003). „Insulin glargine: An updated review of its use in the management of diabetes mellitus”. Drugs. 63 (16): 1743—78. PMID 12904090. doi:10.2165/00003495-200363160-00007.
^ Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. Home, P. D.; Ashwell, S. G. (2002). „An overview of insulin glargine”. Diabetes/Metabolism Research and Reviews. 18 Suppl 3: S57—63. PMID 12324987. doi:10.1002/dmrr.317.
^ Jones R: Insulin glargine (Aventis Pharma). IDrugs. Jones, R. (септембар 2000). „Insulin glargine (Aventis Pharma)”. Idrugs : The Investigational Drugs Journal. 3 (9): 1081—7. PMID 16049868.
^ Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Wang, F.; Carabino, J. M.; Vergara, C. M. (јун 2003). „Insulin glargine: A systematic review of a long-acting insulin analogue”. Clin Ther. 25 (6): 1541—77. PMID 12860485. doi:10.1016/S0149-2918(03)80156-X. , discussion 1539-40. PMID 12860485
^ Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Warren, E.; Weatherley-Jones, E.; Chilcott, J.; Beverley, C. (2004). „Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine”. Health Technology Assessment (Winchester, England). 8 (45): iii, 1—57. PMID 15525480. doi:10.3310/hta8450.
^ Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Owens, D.R.; Bolli, G.B. (октобар 2008). „Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application”. Diabetes Technol Ther. 10 (5): 333—49. PMID 18715209. doi:10.1089/dia.2008.0023. .. PMID 18715209
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Insulin glargine

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Chatterjee, S.; Tringham, J. R.; Davies, M. J. (јул 2006). „Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus”. Expert Opin Pharmacother. 7 (10): 1357—71. PMID 16805721. doi:10.1517/14656566.7.10.1357.

[2] Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;Dunn, C. J.; Plosker, G. L.; Keating, G. M.; McKeage, K.; Scott, L. J. (2003). „Insulin glargine: An updated review of its use in the management of diabetes mellitus”. Drugs. 63 (16): 1743—78. PMID 12904090. doi:10.2165/00003495-200363160-00007.

[3] Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. Home, P. D.; Ashwell, S. G. (2002). „An overview of insulin glargine”. Diabetes/Metabolism Research and Reviews. 18 Suppl 3: S57—63. PMID 12324987. doi:10.1002/dmrr.317.

[4] Jones R: Insulin glargine (Aventis Pharma). IDrugs. Jones, R. (септембар 2000). „Insulin glargine (Aventis Pharma)”. Idrugs : The Investigational Drugs Journal. 3 (9): 1081—7. PMID 16049868.

[5] Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Wang, F.; Carabino, J. M.; Vergara, C. M. (јун 2003). „Insulin glargine: A systematic review of a long-acting insulin analogue”. Clin Ther. 25 (6): 1541—77. PMID 12860485. doi:10.1016/S0149-2918(03)80156-X. , discussion 1539-40. PMID 12860485

[6] Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Warren, E.; Weatherley-Jones, E.; Chilcott, J.; Beverley, C. (2004). „Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine”. Health Technology Assessment (Winchester, England). 8 (45): iii, 1—57. PMID 15525480. doi:10.3310/hta8450.

[7] Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Owens, D.R.; Bolli, G.B. (октобар 2008). „Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application”. Diabetes Technol Ther. 10 (5): 333—49. PMID 18715209. doi:10.1089/dia.2008.0023. .. PMID 18715209

[8] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[9] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]